BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 17, 2024 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Feb. 28, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2024 |
Mar. 31, 2024 |
Jun. 30, 2025 |
Jun. 30, 2024 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Product Information [Line Items] | ||||||||||||
| Amount annually to maintain operating activities | $ (1,059,708) | $ (706,870) | ||||||||||
| Common stock issued for services | $ 60,000,000 | $ 4,687 | $ 4,688 | $ 4,687 | $ 4,688 | $ 3,750 | $ 9,482 | 13,232 | ||||
| Cash on hand | 2,660,590 | 2,660,590 | 2,660,590 | $ 2,212,548 | ||||||||
| Inventory, Net | $ 62,961 | 62,961 | 62,961 | |||||||||
| Research and development costs | $ 107,965 | 99,662 | $ 227,246 | $ 157,109 | ||||||||
| Intellectual Property [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Economic life of patents | 10 years | 10 years | 10 years | |||||||||
| Common Stock [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Common stock issued for services | $ 42 | $ 38 | $ 22 | $ 140 | ||||||||
| Number of common stock shares issued, value | $ 1,500,000 | $ 2,266,000 | ||||||||||
| Number of common stock shares issued, shares | 12,500,000 | 12,500,000 | 13,000,000 | 24,950,000 | ||||||||
| Number of warrants issued | 6,250,000 | 7,000,000 | 7,000,000 | |||||||||
| Private Placement [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Number of common stock shares issued, value | $ 1,179,245 | |||||||||||
| Number of common stock shares issued, shares | 16,132,000 | |||||||||||
| Number of warrants issued | 6,250,000 | 6,250,000 | 6,250,000 | 18,797,000 | ||||||||
| Cash proceeds from warrants | $ 6,250 | |||||||||||
| Brachytherapy Product Line [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Amount annually to maintain operating activities | 3,000,000 | |||||||||||
| Radionuclide Therapy Product Line [Member] | ||||||||||||
| Product Information [Line Items] | ||||||||||||
| Amount annually to maintain operating activities | $ 3,000,000.0 | |||||||||||
| Offering term | Over the next 36 months, the Company believes it will require approximately $9.0 million in additional capital to: (i) fund the FDA approval process to conduct human clinical trials; (ii) conduct Phase I, pilot, clinical trials; (iii) activate several regional clinics to administer IsoPet® across the U.S.; (iv) create an independent production center within the current production site to create a template for future international manufacturing; and (v) initiate regulatory approval processes outside of the U.S. | |||||||||||